When initial androgen-deprivation therapy (ADT) fails to control progression of metastatic prostate cancer, the disease is redefined as castration-resistant prostate cancer (CRPC). Studies have shown that using docetaxel and prednisone to treat men with CRPC only modestly extends median overall survival (OS) to ~19 months.
August 2026 | Volume 19 | No 3
To sign up for our newsletter or print publications, please enter your contact information below.
